Quick Takeaways
- Mark E. Strome filed SCHEDULE 13G/A for Cue Biopharma, Inc. Common Stock, $0.001 par value per share (CUE).
- Disclosed ownership: 5%.
- Date of event: 14 Nov 2022.
Mark E. Strome - 14 Nov 2022 SCHEDULE 13G/A Report for Cue Biopharma, Inc. Common Stock, $0.001 par value per share (CUE)
- Filing Manager
- Mark E. Strome
- Reporting Manager
- Mark E. Strome
- Symbol
- CUE
- Shares outstanding
- 43,411,663 shares
- Disclosed Ownership
- 2,166,242 shares
- Ownership
- 5%
- Form type
- SCHEDULE 13G/A
- Filing time
- 16 May 2025, 16:01:24 UTC
- Date of event
- 14 Nov 2022
- SEC
- View on sec.gov
Quoteable Key Fact
"Mark E. Strome disclosed 5% ownership in Cue Biopharma, Inc. Common Stock, $0.001 par value per share (CUE) on 14 Nov 2022."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 16 May 2025, 16:01.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Mark E. Strome | 5% | 2,166,242 | 50,229 | 2,116,013 | /s/ Mark E. Strome | Mark E. Strome | |
| Strome Mezzanine Fund, LP | 0.11% | 46,103 | 0 | 46,103 | /s/ Mark E. Strome | President of Strome Group, Inc., the general partner of Strome Investment Management, LP, the general partner of Strome Mezzanine Fund, LP | |
| Strome Mezzanine Fund II, LP | 4.4% | 1,907,281 | 0 | 1,907,281 | /s/ Mark E. Strome | President of Strome Group, Inc., the general partner of Strome Investment Management, LP, the general partner of Strome Mezzanine Fund II, LP | |
| Strome Dynasty, LLC. | 0.38% | 162,629 | 0 | 162,629 | /s/ Mark E. Strome | Manager |